PRAC Recommends Product Information of Zolpidem be Updated
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a review of zolpidem-containing medicines, used for the short-term treatment of insomnia (inability to sleep). The benefit–risk balance of these medicines remains positive, but the PRAC recommended changes to the product information, which are aimed at further minimising the known risks of next-morning impaired driving ability and mental alertness (including somnambulism).
The review of zolpidem was initiated after reports of impaired driving or road accidents the morning after patients took the medicine. It is well known that medicines such as zolpidem may cause drowsiness and slower reactions the day after taking the medicine, which could increase the risk of accidents during activities that require alertness such as driving, and the zolpidem product information already contains a warning of this risk. However, it was considered that a detailed review and analysis involving additional information on the benefits and risks of zolpidem, including information on its effectiveness and risks at lower doses, was needed to decide whether any changes should be made to the marketing authorisations of these products across the EU.
The PRAC has now recommended changes to the product information of zolpidem, including further highlighting the risks of impaired driving and mental alertness and strengthening warnings and precautions aimed at minimising these risks. The PRAC considered that the recommended daily dose should remain at 10 mg of zolpidem, and this dose must not be exceeded. Patients should take the lowest effective dose, in a single intake just before going to bed, and the medicine should not be taken again during the same night. In elderly patients and in patients with reduced liver function, the recommended dose remains 5 mg of zolpidem per day. Furthermore it is recommended not to drive or perform activities that require mental alertness until 8 hours after taking zolpidem. Zolpidem should not be taken together with other medicines that have an effect on the central nervous system (brain and spinal cord). Similarly, alcohol or other substances that affect mental function should not be used when taking zolpidem.
The PRAC recommendation will now be sent to the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) for consideration at its meeting on 22–24 April 2014.[1]
Reference
[1] The companies that market zolpidem have the right to ask for a re-examination of the PRAC recommendation within 15 days of receipt of the PRAC recommendation, which would delay the expected time of finalisation of this review.
For more information, click here
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance